MedPath

Progress and Challenges in Developing Blood-Stage Malaria Vaccines

Recent trials of the MSP/RESA (Combination B) vaccine, targeting the blood-stage of malaria, show promise in reducing parasite density but not in preventing clinical malaria episodes. The vaccine's efficacy is variant-specific, highlighting the need for further development and inclusion of all significant allelic types.

Background

Malaria, a life-threatening disease caused by Plasmodium parasites transmitted through mosquito bites, remains a significant global health challenge. The development of effective vaccines is crucial for malaria control. This review focuses on blood-stage vaccines, particularly the MSP/RESA (Combination B) vaccine, which targets the asexual phase of the parasite's life cycle when it resides in red blood cells.

MSP/RESA Vaccine Trials

Five trials involving 217 participants have been conducted to assess the safety and efficacy of the MSP/RESA vaccine. These trials have shown that the vaccine is safe at doses of 13 to 15 µg of each antigen, with no severe or systemic adverse effects reported. However, efficacy trials have yielded mixed results. A small trial with non-immune adults showed no reduction in parasite growth rates after artificial challenge. In contrast, a trial in Papua New Guinea with semi-immune children aged five to nine years demonstrated that the vaccine significantly reduced parasite density in children not pretreated with an antimalarial drug. However, it did not reduce the incidence of clinical malaria episodes.

Variant-Specific Efficacy

The MSP/RESA vaccine's efficacy is MSP2 variant-specific, with a significant reduction in infections with the 3D7 parasite subtype included in the vaccine. This specificity underscores the importance of including all significant allelic types in future vaccine formulations to enhance efficacy across different parasite strains.

Implications for Research and Practice

The findings suggest that blood-stage vaccines, like MSP/RESA, hold promise but require further development to improve their efficacy and applicability. The impact of pretreatment with antimalarial drugs on vaccine trial outcomes also warrants further investigation. As blood-stage vaccines are not yet licensed for use, their implications for clinical practice remain to be determined.

Conclusion

While the MSP/RESA vaccine represents a significant step forward in malaria vaccine development, its variant-specific efficacy and the complexity of malaria's life cycle highlight the challenges in creating a universally effective vaccine. Continued research and development are essential to overcome these hurdles and bring us closer to effective malaria control and eradication.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Genetically Modified Mosquitoes Show Promise in Malaria Vaccine Delivery

Researchers have engineered mosquitoes to deliver a weakened malaria parasite, potentially enhancing immunity against the disease.
A clinical trial showed that 89% of participants who received the GA2 vaccine via mosquito bites developed immunity to malaria.

PfSPZ Vaccine Demonstrates Efficacy Against Malaria in Women Anticipating Pregnancy

The PfSPZ vaccine showed significant efficacy against _P. falciparum_ parasitemia in women anticipating pregnancy, offering a potential preconception immunization strategy.
In phase 2 trials, both doses of the PfSPZ vaccine demonstrated efficacy against parasitemia and clinical malaria at years 1 and 2 in women of childbearing age.

Experimental Malaria Vaccine Shows Lasting Protection in Clinical Trials

An experimental malaria vaccine, PfSPZ Vaccine, demonstrated significant protection against parasite infection and clinical malaria for up to two years in healthy Malian adults.
The vaccine also showed promise in protecting women from malaria during pregnancy, with efficacy rates ranging from 49% to 86% in an exploratory analysis.

Blood-stage Malaria Vaccine Candidate RH5.1/Matrix-M Trial in Tanzania

A phase 1b trial of the blood-stage malaria vaccine candidate RH5.1/Matrix-M has been conducted in healthy Tanzanian adults and children, marking a significant step in malaria vaccine development.

RH5.1/Matrix-M Vaccine Shows Promising Efficacy Against Malaria in African Children

A phase 2b trial in Burkina Faso demonstrates the RH5.1/Matrix-M malaria vaccine's safety and efficacy, showing a 55% vaccine efficacy in a delayed third-dose regimen among children aged 5-17 months.

Monoclonal Antibody CIS43LS Shows Promise in Preventing Malaria Infection in African Adults

A Phase 2 clinical trial demonstrated that a single dose of the monoclonal antibody CIS43LS safely protected adults from malaria infection during a six-month malaria season in Mali.
The high dose (40 mg/kg) of CIS43LS was 88.2% effective in preventing malaria infection over 24 weeks, while the lower dose (10 mg/kg) showed 75% efficacy.

Monoclonal Antibody Shows Promise in Preventing Malaria in Early Trial

A Phase 1 clinical trial demonstrated that a single dose of the monoclonal antibody CIS43LS safely prevented malaria in individuals exposed to the parasite for up to 9 months.
The experimental antibody, developed at NIH, binds to a conserved site on the Plasmodium falciparum sporozoite surface, neutralizing the parasite before it can cause infection.

Phase I/IIa Clinical Trial of RH5.1/AS01B Vaccine for Blood-Stage Malaria Shows Promising Safety and Immunogenicity

A first-in-human, open-label, non-randomized, multi-center, dose escalation Phase I/IIa clinical trial evaluated the safety, immunogenicity, and efficacy of the RH5.1/AS01B vaccine against blood-stage malaria. The study involved healthy, malaria-naive adults aged 18 to 45, demonstrating the vaccine's potential to reduce parasite multiplication rate and its safety profile across different doses.

NIAID's LMIV Spearheads Development of Novel Malaria Vaccines Targeting Transmission

The Laboratory of Malaria Immunology and Vaccinology (LMIV) is leading efforts in developing malaria vaccines, focusing on reducing severe disease and eliminating malaria in low-transmission areas.
LMIV's research spans basic discovery to product development, facilitating rapid translation of ideas into clinical trials, with a focus on understanding human immunity and responses to infection.

Reference News

[1]
Vaccines for preventing malaria (blood‐stage) - PMC
pmc.ncbi.nlm.nih.gov · Oct 18, 2006

The MSP/RESA (Combination B) malaria vaccine, targeting the blood stage of the parasite, showed promise in reducing para...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy